Literature DB >> 28568312

Autoimmune comorbidity in achalasia patients.

Fernanda Romero-Hernández1, Janette Furuzawa-Carballeda2, Gabriela Hernández-Molina2, Edgar Alejandro-Medrano1, Carlos A Núñez-Álvarez2, Diego F Hernández-Ramírez2, Daniel Azamar-Llamas2, Elizabeth Olivares-Martínez2, Blanca Breña1, Axel Palacios1, Miguel A Valdovinos3, Enrique Coss-Adame3, Bárbara Ramos-Ávalos1, Samuel Torres-Landa1, Axel A Hernández-Ávila1, Athenea Flores-Nájera1, Gonzalo Torres-Villalobos1.   

Abstract

BACKGROUND AND AIM: Idiopathic achalasia is a rare esophageal motor disorder. The disease state manifests local and systemic inflammation, and it appears that an autoimmune component and specific autoantibodies participate in the pathogenesis. The study aims to determine the prevalence of autoimmune and chronic inflammatory diseases in patients with achalasia and compare the results with those from patients with gastroesophageal reflux disease (GERD).
METHODS: It was a cross-sectional and included 114 patients with idiopathic achalasia and 114 age-matched and sex-matched control patients with GERD. Data on the presence of autoimmune and inflammatory diseases, the time of presentation, and any family history of autoimmune disease were obtained from the hospital's medical records.
RESULTS: Seventy three (64%) were female patients (mean age: 42.3 ± 15.5; median disease duration: 12 months). We identified the presence of autoimmune disease in 19 patients with achalasia (16.7%), hypothyroidism was the main diagnosis, and it was present in 52.6% of patients compared with 4.2% in controls. Thirteen of the 19 achalasia patients (68.4%) with autoimmune disease had history of familial autoimmunity. We identified 11 achalasia (9.6%) and 5 GERD patients (4.16%) with an inflammatory condition. Compared with the GERD, the achalasia group was 3.8 times more likely to have an autoimmune disease (95% CI: 1.47-9.83), 3.0 times more likely to have thyroidopathies (95% CI: 1.00-9.03), and 3.02 times more likely to suffer from any chronic inflammatory disease (95% CI: 1.65-6.20).
CONCLUSIONS: The non-negligible number of patients with autoimmune diseases identified among the patients with idiopathic achalasia supports the hypothesis that achalasia has an autoimmune component.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  achalasia; antinuclear antibodies; autoimmune diseases; chronic inflammatory diseases

Mesh:

Year:  2018        PMID: 28568312     DOI: 10.1111/jgh.13839

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

Review 1.  Updated Systematic Review of Achalasia, with a Focus on POEM Therapy.

Authors:  Mitchell S Cappell; Stavros Nicholas Stavropoulos; David Friedel
Journal:  Dig Dis Sci       Date:  2019-08-27       Impact factor: 3.199

Review 2.  Achalasia.

Authors:  Edoardo Savarino; Shobna Bhatia; Sabine Roman; Daniel Sifrim; Jan Tack; Sarah K Thompson; C Prakash Gyawali
Journal:  Nat Rev Dis Primers       Date:  2022-05-05       Impact factor: 52.329

3.  Autoimmune and viral risk factors are associated with achalasia: A case-control study.

Authors:  Charles E Gaber; Cary C Cotton; Swathi Eluri; Jennifer L Lund; Timothy M Farrell; Evan S Dellon
Journal:  Neurogastroenterol Motil       Date:  2021-12-26       Impact factor: 3.960

4.  An original Eurasian haplotype, HLA-DRB1*14:54-DQB1*05:03, influences the susceptibility to idiopathic achalasia.

Authors:  Janette Furuzawa-Carballeda; Joaquín Zuñiga; Diana I Hernández-Zaragoza; Rodrigo Barquera; Eduardo Marques-García; Luis Jiménez-Alvarez; Alfredo Cruz-Lagunas; Gustavo Ramírez; Nora E Regino; Ramón Espinosa-Soto; Edmond J Yunis; Fernanda Romero-Hernández; Daniel Azamar-Llamas; Enrique Coss-Adame; Miguel A Valdovinos; Samuel Torres-Landa; Axel Palacios-Ramírez; Blanca Breña; Edgar Alejandro-Medrano; Axel Hernández-Ávila; Julio Granados; Gonzalo Torres-Villalobos
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

5.  Gelatinase B/Matrix Metalloproteinase-9 as Innate Immune Effector Molecule in Achalasia.

Authors:  Janette Furuzawa-Carballeda; Lise Boon; Gonzalo Torres-Villalobos; Fernanda Romero-Hernández; Estefania Ugarte-Berzal; Erik Martens; Jennifer Vandooren; Vasily Rybakin; Enrique Coss-Adame; Miguel Valdovinos; David Velazquez-Fernández; Ghislain Opdenakker
Journal:  Clin Transl Gastroenterol       Date:  2018-11-19       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.